source
- Sanofi stops development of eczema drug amlitelimab after mixed trial resultsSanofi announced on Friday that it is halting further development of amlitelimab for atopic dermatitis, a drug it had once promoted as a potential successor to its blockbuster Dupixent. The compan…
- Fatal gene-editing trial in China sparks ethics and oversight concernsA six-year-old girl in China died after receiving an experimental brain-directed CRISPR therapy, according to a report in Science. The tragedy has intensified calls for stronger ethical review and…